NR (Nicotinamide Riboside): Complete Guide

Nicotinamide riboside — most commonly referred to as NR — is the NAD+ precursor with the longest continuous track record in human clinical research. While NMN has attracted more recent attention, NR has been studied in controlled human trials since 2016 and has accumulated a broader published evidence base than any other NAD+ precursor supplement. It is a form of vitamin B3, structurally distinct from the more familiar niacin and nicotinamide, and its ability to raise NAD+ levels in human blood has been replicated across more than a dozen independent trials. This guide covers everything you need to make an informed decision about NR: what it is, how it works, what the evidence shows across a range of health areas, how to dose it, and what to look for when buying.

What NR Is and Where It Sits in the NAD+ Pathway

NR is a naturally occurring nucleoside — a structural relative of the building blocks of DNA and RNA — first identified as a component of cow’s milk in the early 2000s. It is classified as a form of vitamin B3, making it a cousin of niacin and nicotinamide, though it has a distinct chemical structure and a different metabolic route into NAD+.

In the NAD+ biosynthesis pathway, NR sits two steps upstream of NAD+. After absorption, NR is phosphorylated by an enzyme called NRK (nicotinamide riboside kinase) to produce NMN. NMNAT enzymes then convert that NMN into NAD+. This two-step conversion means NR is one step further from NAD+ than NMN — which enters the pathway at the NMN stage — but NR compensates with a meaningful structural advantage: it lacks the phosphate group that makes NMN relatively large and charged, allowing it to cross cell membranes through equilibrative nucleoside transporters without requiring prior conversion. Once inside the cell, NRK converts it to NMN, and NMNAT completes the journey to NAD+.

The complete biochemistry of these pathways is covered in our article on the NAD+ pathway explained, and the comparison between NR and NMN as supplement choices is covered in our dedicated NMN vs. NR article. This guide focuses specifically on NR’s evidence base and practical use.

NR’s Regulatory and Safety History

NR has a notably cleaner regulatory history than NMN. ChromaDex, the company that developed the commercial NR ingredient Niagen, submitted it through both the FDA’s New Dietary Ingredient (NDI) notification process and the Generally Recognized as Safe (GRAS) notification process. In 2016, the FDA issued a no-questions letter to ChromaDex’s GRAS notification for nicotinamide riboside chloride — meaning the agency did not challenge the company’s safety assessment. The European Food Safety Authority has similarly assessed NR and authorized its use as a novel food. NR has never faced the regulatory uncertainty that NMN encountered between 2022 and 2025. This stable regulatory standing, combined with its longer published research history, is one of NR’s practical advantages over NMN for consumers who prioritize regulatory certainty.

What Human Clinical Trials Have Found

NR’s clinical research base is broader and in some respects more diverse than NMN’s, spanning cardiovascular health, metabolic function, neurological disease, and long COVID — reflecting both the longer time NR has been available for research and the greater number of independent research groups working with it.

NAD+ Elevation: The Consistent Finding Across All Trials

The most reliably reproduced finding across NR trials is that it raises blood NAD+ levels in a dose-dependent manner. The foundational study in this regard was conducted by Conze, Brenner, and Kruger at the University of Iowa and published in Scientific Reports in 2019. This was the largest NR trial at the time, enrolling 132 healthy overweight adults in a randomized, double-blind, placebo-controlled design. It found that NR at doses of 100 mg, 300 mg, and 1,000 mg per day raised whole blood NAD+ by 22%, 51%, and 142% respectively within two weeks, with increases maintained throughout the eight-week study. No flushing was reported at any dose, and no significant differences in adverse events were observed between NR and placebo groups. This dose-dependent relationship — more NR, more NAD+ — has been replicated in subsequent trials, establishing the pharmacokinetic picture of NR in humans with considerable confidence.

Cardiovascular Health: The Most Developed Human Evidence

Among the health domains studied in NR trials, cardiovascular function has the most developed human evidence. The Martens et al. 2018 trial — a randomized, double-blind, crossover study at the University of Colorado — found that six weeks of NR supplementation at 1,000 mg per day in healthy middle-aged and older adults raised blood NAD+ levels significantly and, in exploratory analyses, suggested potential for reducing systolic blood pressure and arterial stiffness. These effects were most pronounced in participants with elevated baseline blood pressure, suggesting that benefit may concentrate in those with the greatest cardiovascular risk burden.

The most significant NR cardiovascular trial to date was published in Nature Communications in 2024: the NICE trial (McDermott et al.), which enrolled 90 people with peripheral artery disease (PAD) — a condition characterized by reduced blood flow to the limbs due to arterial narrowing. This rigorous, randomized, double-blind trial found that NR meaningfully improved six-minute walk test performance compared to placebo. Notably, adding resveratrol to NR did not produce additional benefit over NR alone in this trial — a finding worth knowing for those considering combination products. PAD represents a population with genuine cardiovascular impairment and meaningful NAD+ deficit, and the trial’s positive walking performance outcome is one of the more clinically significant human findings for any NAD+ precursor.

Neurological Applications: Active and Expanding Research

NR has attracted substantial neurological research interest, driven by NAD+’s importance for brain energy metabolism and DNA repair. Several well-designed trials have been completed or are ongoing.

In Parkinson’s disease, a Norwegian research group published the NADPARK trial in 2022, which found that NR supplementation raised brain NAD+ levels in Parkinson’s patients and was associated with a slight improvement in clinical scores. The NR-SAFE trial, also from the Norwegian group, confirmed that NR at 3,000 mg per day for 30 days was well tolerated in Parkinson’s patients with no moderate or severe adverse events — a safety finding that opened the door for higher-dose Phase II trials. This dose tolerance data is the most extensive for any NAD+ precursor in a clinical population.

In cognitive decline, a 2025 crossover trial (Wu et al., Alzheimer’s & Dementia: Translational Research & Clinical Interventions) examined 1,000 mg per day of NR for eight weeks in older adults with subjective cognitive decline and mild cognitive impairment. The study assessed both cognitive function and plasma Alzheimer’s disease biomarkers. Results showed NR’s effects on cognitive biomarkers in this population, contributing to the growing body of evidence that NAD+ precursor supplementation may be particularly relevant for neurological aging — an application with substantial ongoing trial activity.

In long COVID, a 2025 randomized controlled trial published in eClinicalMedicine (The Lancet) tested 2,000 mg per day of NR for up to 20 weeks in 58 people with long COVID, whose symptoms include cognitive difficulties and mitochondrial dysfunction. The trial evaluated NAD+ levels and cognitive and symptom recovery. This is one of the first well-controlled trials examining NR in a post-viral context — an area of active scientific interest.

What the Trials Have Not Established

As with NMN, the NR evidence base has important limits that honest coverage requires acknowledging. Most trials are small and short. The NICE PAD trial is one of the few with a clinically meaningful endpoint (walking performance) rather than a surrogate marker. No NR trial has demonstrated extension of lifespan, prevention of Alzheimer’s disease, or reversal of aging in healthy adults. The neurological trials are among the most promising directions in the field, but results to date are preliminary. The mechanistic case for NR’s relevance to brain aging is strong; the clinical proof in healthy populations is still accumulating. Full details of the human clinical evidence are in our article on NR clinical trial results.

NR Safety Profile: Among the Best-Established of Any Supplement

NR’s safety profile is, by supplement standards, unusually well characterized. It has been studied in human trials at doses ranging from 100 mg to 3,000 mg per day, across healthy adults, overweight adults, older adults, people with PAD, Parkinson’s patients, and long COVID patients. No trial has identified clinically significant adverse effects directly attributable to NR. The most commonly reported side effects across trials are mild and transient: occasional nausea, stomach discomfort, headache, or fatigue, occurring at rates similar to placebo in most studies. NR does not cause the niacin flush that limits high-dose niacin supplementation.

One metabolic finding worth noting is a slight, transient elevation in homocysteine levels observed in some NR trials. The NR-SAFE Parkinson’s trial noted a slight initial rise in serum homocysteine levels at the 3,000 mg dose, though the researchers found the integrity of the methyl donor pool remained intact. Homocysteine elevation is a theoretical concern because elevated levels are associated with cardiovascular risk, and this is one of the reasons some practitioners recommend pairing NR (and NMN) with TMG (trimethylglycine) to support methylation. This concern is not unique to NR — it applies to all NAD+ precursors at higher doses — and has not translated into observed cardiovascular harm in trial participants. It is nonetheless worth knowing about, and our article on TMG explains the methylation context.

The GRAS designation for NR from the FDA, combined with the EFSA novel food authorization in Europe, gives NR a regulatory safety foundation that few supplements can claim. A full safety review is in our article on Is NR Safe?

NR Dosage: What the Evidence Supports

Human trials have used NR doses ranging from 100 mg to 3,000 mg per day, with most commercial products positioned at 250 mg to 1,000 mg per day. The most extensively studied and commonly recommended dose is 300 mg per day — the dose used in numerous trials and the standard recommendation from ChromaDex for Tru Niagen. At this dose, the Conze et al. 2019 trial demonstrated a 51% increase in whole blood NAD+ within two weeks, maintained throughout the study.

Higher doses raise NAD+ more — the 1,000 mg dose in the same trial produced a 142% increase — and appear safe based on available data. Whether the higher NAD+ elevation from 1,000 mg versus 300 mg translates into proportionally greater health benefits in otherwise healthy adults is not established. For people with specific conditions being studied at higher doses (Parkinson’s, PAD, long COVID), the research protocols use doses of 1,000 mg or above. For general healthspan purposes in healthy middle-aged adults, 300 mg to 500 mg per day represents a reasonable and well-evidenced range.

As with NMN, the right dose is likely to vary by individual, and baseline NAD+ status — difficult to assess without testing — may influence how much benefit a given dose provides. Starting at 300 mg per day and assessing response over eight to twelve weeks before adjusting is a reasonable protocol for most people.

How to Choose an NR Supplement: Key Criteria

The NR market is considerably more consolidated than the NMN market. ChromaDex’s Niagen ingredient, which has been used in the majority of published human NR trials, is the most thoroughly validated commercial NR source. However, other NR products exist, and not all have equivalent documentation.

The same quality criteria that apply to NMN apply to NR, with some NR-specific considerations.

The Niagen Ingredient: Why It Matters for Buyers

When evaluating NR products, noting whether the product uses ChromaDex’s Niagen ingredient or a generic NR is meaningful. Niagen has been the specific NR form tested in the majority of human clinical trials, has successfully completed the FDA’s NDI and GRAS notification processes, and is manufactured under cGMP standards with documented quality control. Many of the strongest safety and efficacy claims made about NR in the scientific literature specifically refer to this form. Products using uncharacterized or undisclosed NR sources cannot directly claim the same trial backing. This does not mean only Niagen-based products are worth considering, but it means buyers should be more rigorous about quality documentation — particularly third-party COAs — for non-Niagen NR products.

Third-Party Testing and Certificates of Analysis

As with any supplement, a publicly available Certificate of Analysis from an accredited, ISO 17025-certified independent laboratory is the baseline quality requirement. The COA should confirm NR identity and purity, lot number, and absence of concerning contaminants. For NR specifically, confirming that the product contains nicotinamide riboside chloride (the stable salt form used in trials) rather than a less characterized form is worth verifying. Products that cannot or will not provide COAs on request should be avoided.

Dosage and Value Considerations

NR tends to be less expensive per milligram than NMN, and this cost advantage compounds at the doses typically used. At a standard 300 mg per day dose, an NR supplement is likely to cost meaningfully less over twelve weeks than an equivalent NMN regimen — a practical consideration for people planning long-term supplementation. Combination products that include NR alongside other longevity compounds (pterostilbene is a common pairing, as discussed in our article on pterostilbene vs. resveratrol) may offer additional value if the companion ingredients are dosed meaningfully rather than as label decoration.

NR in the Context of a Broader Longevity Stack

NR is most commonly used either as a standalone NAD+ precursor or as part of a broader longevity supplement protocol. The most frequently discussed companion supplements follow the same logic as with NMN: resveratrol to activate the sirtuin proteins that the raised NAD+ will fuel, and TMG to support methylation. The NICE PAD trial’s finding that resveratrol did not add benefit to NR alone in that specific population is worth noting — it does not invalidate the mechanistic case for the combination, but it is a reminder that clinical outcomes in specific populations do not always match mechanistic predictions.

For those deciding between NR and NMN as their primary NAD+ precursor, the evidence does not clearly favor one over the other for most people. NR has a longer research track record and stable regulatory history; NMN is one step closer to NAD+ in the pathway and has a growing body of human evidence. Our full comparison is in the NMN vs. NR article. For those new to NAD+ supplementation, our beginner’s stack guide covers how to approach the category practically.

Frequently Asked Questions About NR Supplements

What Is the Difference Between NR and Niacin?

Both NR and niacin (nicotinic acid) are forms of vitamin B3 and both raise NAD+ levels, but they do so through different biochemical routes and with different side effect profiles. Niacin works through the Preiss-Handler pathway and produces intermediates that activate skin capillary receptors, causing the characteristic niacin flush — uncomfortable warmth and redness that can be severe at high doses. NR enters the salvage pathway directly and bypasses these intermediates entirely, which is why NR does not cause flushing even at doses of 1,000 mg or more. For people who want to raise NAD+ without the flush, NR is generally preferred over high-dose niacin.

How Quickly Does NR Raise NAD+ Levels?

The Conze et al. 2019 trial measured NAD+ increases within two weeks at all doses tested (100 mg, 300 mg, and 1,000 mg per day). This is consistent with what has been observed across subsequent trials — NAD+ elevation is detectable relatively quickly, typically within one to two weeks of consistent supplementation. Subjective effects, if experienced, generally emerge over four to eight weeks. Changes in clinical markers such as blood pressure or metabolic parameters, where they have been observed, typically required six to twelve weeks in trial conditions.

Can NR Be Taken Alongside NMN?

Yes, and some premium combination products include both NR and NMN at partial doses of each. The rationale is that the two precursors may have somewhat different tissue distribution and cellular uptake characteristics, potentially providing broader coverage than either alone. There is limited clinical evidence specifically validating the combination over a well-dosed single precursor. Taking full recommended doses of both simultaneously may result in higher total NAD+ elevation but does not have clear head-to-head evidence of proportionally greater benefit. Our article on taking NMN and NR together covers this in detail.

Does NR Affect Homocysteine Levels?

Some NR trials, particularly at higher doses, have observed a slight transient elevation in blood homocysteine levels. This is thought to occur because NAD+ metabolism generates nicotinamide as a byproduct, and nicotinamide metabolism can draw on methyl groups that would otherwise be used to process homocysteine. The effect has been modest and has not produced observed clinical harm in trial participants. Pairing NR with TMG (trimethylglycine) is commonly recommended as a precaution, since TMG is a methyl donor that can help offset this effect. People with elevated baseline homocysteine or known methylation issues should discuss NR supplementation with their physician before starting.

Is Tru Niagen the Only Reputable NR Product?

Tru Niagen, which uses ChromaDex’s Niagen ingredient, has the most extensively documented clinical backing of any NR product because it has been the NR form used in the majority of published human trials. However, it is not the only reputable option. Other NR products using the Niagen ingredient are sold under different brand names and may offer better value per milligram. Non-Niagen NR products can also be legitimate if they provide verifiable third-party COAs from accredited laboratories confirming identity, purity, and potency of nicotinamide riboside chloride. The key is documentation, not brand name. Our dedicated guide on how to choose an NR supplement covers the full selection criteria.